In an ironic twist, the institute which employs James Sherley, one of two scientists who pursued to block research on stem cells financed by the federal government, is weighing on the other side. Today the Boston Biomedical Research Institute (BBRI) requested to support the call for a preliminary injunction on August 23 that temporarily closed National Institutes of Health (NIH) funded research on human embryonic stem cells (hESCs ) of the government.
CSEC wants to join an amicus curiae (friend of the court) previously filed by the Coalition for the Advancement of Medical Research, the State of Wisconsin, and genetic Policy Institute. In a move of 3 pages, the institute, which has 25 principal investigators, said it wants to expand its regenerative biology program funded by the NIH using human adult stem cells to hESCs include "but is limited by the injunction to do. CSEC is severely limited in the development of potential treatments for human disease. " In addition, the research center of muscular dystrophy NIH-funded Institute would like to study hESC with mutations of this disease, but notes that it did not accept an offer of such cells because of the injunction .
This supports "the perspective of the parties amicus they provided the Court with regard to the severe negative impact of the preliminary injunction on patients who should benefit from advances in medical science. .. and the strong public interest in the continued funding of [hESC] research, "says BBRI motion, filed in the US Court of Appeals for the DC Circuit.
Sherley and another scientist argue in their suit that the NIH hESC policy is illegal and harms their chances of winning funding to study adult stem cells.
the Appeals court will hear oral arguments on December 6. Meanwhile, Royce Lamberth chief judge of the US district court in Washington, DC, could decide on the underlying case and issue a permanent injunction. Any decision is subject to appeal.
0 Komentar